You are here
VIROGENOMICS, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
HLA-DR4-derived RTLs for Treating Rheumatoid Arthritis
Amount: $100,548.00DESCRIPTION (provided by applicant): The specific goal of this Phase I STTR is to design, manufacture, characterize and evaluate a set of therapeutic agents that can control the pathogenic CD4+ T cell ...
SBIRPhase I2005Department of Health and Human Services National Institutes of Health -
Development of a T cell specific multiple sclerosis drug
Amount: $720,140.00DESCRIPTION (provided by applicant): The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS). The lead compound in the current propo ...
STTRPhase II2004Department of Health and Human Services National Institutes of Health -
HLA-DQ-derived RTLs for Treatment of Celiac Disease
Amount: $102,839.00DESCRIPTION (provided by applicant): The specific goals of this Phase I STTR are to design, manufacture, and characterize a set of therapeutic tools that can control the pathogenic CD4+ T cells that m ...
STTRPhase I2004Department of Health and Human Services National Institutes of Health -
HLA-DQ-derived RTLs for Treatment of Celiac Disease
Amount: $102,839.00DESCRIPTION (provided by applicant): The specific goals of this Phase I STTR are to design, manufacture, and characterize a set of therapeutic tools that can control the pathogenic CD4+ T cells that m ...
SBIRPhase I2004Department of Health and Human Services National Institutes of Health -
Development of a T cell specific multiple sclerosis drug
Amount: $720,140.00DESCRIPTION (provided by applicant): The broad, long-term objective of this project is to develop a new class of drugs for treatment of multiple sclerosis (MS). The lead compound in the current propo ...
SBIRPhase II2004Department of Health and Human Services National Institutes of Health -
Identifying cellular genes as anti-HIV drug targets
Amount: $99,808.00N/A
STTRPhase I2003Department of Health and Human Services National Institutes of Health -
Development of a T cell specific multiple sclerosis drug
Amount: $99,808.00DESCRIPTION (provided by applicant): The goal of this project is to develop a family of marketable therapeutic drugs for treating mulitple sclerosis (MS) that is directed at the specific autoimmune re ...
STTRPhase I2003Department of Health and Human Services National Institutes of Health -
Osteopontin, a novel neuroprotectant in brain ischemia
Amount: $99,703.00DESCRIPTION (provided by applicant): The overall goal of this project is to develop novel neuroprotective or therapeutic treatments for stroke, the third leading cause of death and disability in the U ...
STTRPhase I2003Department of Health and Human Services National Institutes of Health -
TREATMENT OF HCMV IN TRANSPLANT VASCULAR SCELROSIS
Amount: $96,845.00DESCRIPTION (provided by applicant): Transplant Vascular Sclerosis (TVS) is an accelerated form of arteriosclerosis that is responsible for significant number of cases of chronic rejection in solid or ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health -
A METHOD FOR TREATING HCMV IN VASCULAR DISEASE
Amount: $96,105.00Cardiovascular disease remains the most common cause of death in the United States. While atherosclerosis accounts for the majority of these deaths, other vasculopathies such as restenosis after ...
SBIRPhase I2002Department of Health and Human Services National Institutes of Health
